Cost effectiveness analysis of a fixed dose combination pill for primary prevention of cardiovascular disease from an individual participant data meta-analysis.
Authors : Andre Lamy, Wesley Tong, Philip Joseph, Peggy Gao, Mark D Huffman, Gholamreza Roshandel, Reza Malekzadeh, Patricio Lopez-Jaramillo, *Prem Pais*, *Denis Xavier*, Alvaro Avezum, Antonio L Dans, Habib Gamra, Salim Yusuf.
Publication Year : 2024
Abstract :
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00230-X/fulltext
Background
Cardiovascular disease (CVD) continues to impart a large burden on the global population, especially in lower income countries where affordability limits the use of cardiovascular medicines. A fixed dose combination strategy of at least 2 blood pressure lowering medications and a statin with aspirin in a single pill has been shown to reduce the risk of incident CVD by 38% in primary prevention in a recent meta-analysis. We report the in-trial (median follow-up: 5 years) cost-effectiveness of a fixed dose combination (FDC) pill in different income groups based on data from that meta-analysis.